News

Cigna Options Trading Insights: Current Market Dynamics

Cigna Options Trading Insights: Current Market Dynamics

Understanding Recent Options Trading in Cigna

In the world of options trading, analysts have noticed a significant shift in the sentiment surrounding Cigna (NYSE: CI). The latest evaluations indicate a strong bearish outlook, as revealed by the analysis of unusual trades relating to this health insurance and pharmacy services provider.

Looking closely at the data, it appears that approximately 31% of traders have adopted a bullish outlook, while a majority, 68%, are bearish. Among the trades identified, 13 were puts accounting for a hefty value of over $1.3 million, compared to just 3 calls, amounting to approximately $247,758.

Examining Projected Price Targets

Analysts have focused on the volume and open interest reflected in these options contracts. The trend shows that significant traders, often referred to as 'whales,' have set their sights on pricing levels between $270.00 and $310.00 for Cigna in the past quarter. This range indicates the expected volatility in CI's stock price.

Volume and Open Interest Insights

The analysis of volume and open interest is crucial for traders engaging in options. Assessing these metrics provides valuable insights into the liquidity and overall interest surrounding Cigna's options at various strike prices. An overview of the recent trends indicates an evolving narrative around both call and put trades, highlighting the substantial options activity over the last month.

Recent Significant Options Activity

Recently, several noteworthy options trades were executed with various sentiments:

  • Put Trade: Close to $713.3K in bearish sentiment targeting a strike price of $295.00.
  • Call Trade: A bullish sweep was noted with an investment of $172.0K at a strike price of $300.00.
  • Put Trade: Another bearish assessment valued at $90.7K, set for a strike price of $292.50.
  • More Puts: Additional $88.1K trade earmarked for a strike at $310.00.

About Cigna

Cigna is a health services organization that excels in providing pharmacy benefit management and health insurance. Following its strategic merger with Express Scripts in 2018, Cigna has significantly amplified its specialty pharmacy and PBM services. Currently, their most substantial contracts are with the Department of Defense and major insurers like Centene. As of the latest figures, Cigna covers around 17 million members in the U.S. and 2 million internationally.

With a closer look at their operations, it becomes evident why analysts are focusing on Cigna's stock amidst the evolving market conditions.

Cigna's Market Position Today

  • The stock is experiencing a trading volume of around 716,139 shares, with CI's price showing an increment of 0.89%, currently standing at $302.49.
  • Recent analyses indicate that the Relative Strength Index (RSI) indicates a neutral position, keeping investors cautiously optimistic.
  • Investors should prepare for the upcoming earnings announcement, which is expected shortly.

Expert Opinions on Cigna

Market sentiment remains robust as five respected analysts have weighed in on Cigna's future, projecting a consensus price target of $368.60. This shows a strong belief in the potential of the stock despite the headwinds faced with options trading.

Some recent expert assessments include:

  • An analyst from Oppenheimer continues to endorse a target of $375.
  • Another expert from UBS maintains a bullish outlook with a forecast of $390.
  • Piper Sandler has slightly adjusted their target to $348 but retains their positive stance.
  • Two analysts from Stephens & Co. and Cantor Fitzgerald uphold their Overweight ratings, recommending respective targets of $380 and $350.

Options trading carries inherent risks but also offers potential rewards. Astute traders must continually educate themselves, calibrate their strategies, and vigilantly monitor market dynamics.

Frequently Asked Questions

What is the current sentiment regarding Cigna's stock?

Recent analyses indicate a predominantly bearish sentiment among options traders, with 68% showing negativity towards Cigna.

What price range have analysts targeted for Cigna?

Analysts are targeting a price range between $270.00 and $310.00 for Cigna based on recent options trading activities.

How many members does Cigna cover?

Cigna covers approximately 17 million members in the United States and an additional 2 million internationally.

What was the market response to Cigna recently?

Cigna's stock recently showed an increase of 0.89%, priced at $302.49, with a trading volume of 716,139 shares.

Are there upcoming earnings announcements for Cigna?

Yes, investors expect an earnings announcement for Cigna in the near future, creating a sense of anticipation in the market.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Gaine Expands Healthcare Data Solutions Ahead of HLTH 2026

Updated Category News Views 184

Ever felt like healthcare systems are still stuck in a bygone era, struggling with data flinging through the void? Well, Gaine Technology is throwing down its gauntlet to change that narrative. Successful in pharmaceuticals and life sciences, they're turbocharging their Consent and Preference Management solution across the vast, tangled web of healthcare markets just in...

Continue Reading
Innovent's Seven Drugs Leap onto 2026 Reimbursement Chart

Updated Category News Views 223

A Bold Move in Biopharmaceuticals Innovent Biologics just pulled a rabbit out of their hat. Seven of their cutting-edge meds made it onto China's National Reimbursement Drug List for 2026. This isn't just a spreadsheet entry—it's a lifeline thrown to patients across the oncology, metabolic, and autoimmune landscapes, as well as a financial booster for Innovent (HKEX:...

Continue Reading
El Pollo Loco Faces Class Action Over Wage Practices

Updated Category News Views 222

Alright, here's where things start sizzling—El Pollo Loco, the fast-food chicken chain whose name translates to 'The Crazy Chicken'—is in a legal pickle. The lawsuit hanging over their heads could spell a sticky situation for them and possibly ripple through the fast-food industry. The suit, filed by the steadfast firm Blumenthal Nordrehaug Bhowmik De Blouw LLP, has...

Continue Reading
HiTHIUM Joins Cambridge to Boost Global Energy Storage

Updated Category News Views 341

HiTHIUM and Cambridge's New Energy Venture There's a big splash coming out of Xiamen, folks. HiTHIUM, a heavyweight in the energy storage sector, has decided to team up with the University of Cambridge. They inked a deal aiming to bridge the academic ivory tower with industrial grit, focusing on long-duration energy storage. It was all sealed during the Global Energy...

Continue Reading
Ecopetrol Sidesteps Hefty Fines After Investigation Closure

Updated Category News Views 174

Colombian Watchdog Gives Ecopetrol a Pass It's like dodging a bullet in a duel at high noon. The Superintendency of Industry and Commerce (SIC) has finally closed its investigation into Ecopetrol S.A. and its subsidiaries, CENIT and OCENSA, after a probe two years in the making. The stakes were sky-high, folks. We're talkin' about just shy of 530 billion Colombian pesos...

Continue Reading
Webull Faces Class Action: Key Details for Investors

Updated Category News Views 136

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

Continue Reading
Greenberg Traurig's Brad Kaufman: A Mentor of Resolute Impact

Updated Category News Views 300

A Milestone for Mentorship at Greenberg Traurig In the often cutthroat jungle of law, finding someone who actually gives a damn about you is as rare as finding a unicorn. Yet, there it is—Brad Kaufman, at the helm of Greenberg Traurig's professional development, proving that mentorship can be more than just a checkbox on a quarterly review. Award for Exceptional...

Continue Reading
Fluence Energy Faces Leadership Departures Amid Legal Woes

Updated Category News Views 106

Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....

Continue Reading
CARsgen's CAR-T Breakthrough on China's Insurance List

Updated Category News Views 136

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

Continue Reading
AppLovin Legal Woes: A Deep Dive into Investor Claims

Updated Category News Views 153

AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...

Continue Reading

Top 5 Most Recently Viewed Articles

DoorDash Enters Same-Day Electronics Delivery Market

Updated Category News Views 111

Is DoorDash Changing Its Delivery Playbook? Here's the scoop: DoorDash is venturing into the electronics delivery sector, offering same-day services. We're not talking burgers or late-night sushi anymore—now it's all about those last-minute tech needs like chargers, earbuds, and monitors. It's a smart move, given our reliance on technology to stay connected and...

Continue Reading
Scarlet by RedDrop Earns Esteemed Award for Fundability

Updated Category News Views 251

Scarlet by RedDrop Recognized as a Top Fundable Company Scarlet by RedDrop, a pioneering brand in puberty and period care, has recently achieved a significant milestone. The company has been recognized as one of the Most Fundable Companies by Pepperdine Graziadio Business School, highlighting its impressive growth potential and mission-driven approach. Empowering Young...

Continue Reading
Westpac Predicts RBA's Interest Rate Cuts to Start in May 2025

Updated Category News Views 362

Westpac Forecasts RBA Rate Cuts to Commence in May 2025 According to the latest insights from Westpac, the Reserve Bank of Australia (RBA) is anticipated to start reducing interest rates from May 2025, deviating from prior expectations of an earlier cut in February. This adjustment comes as the central bank is expected to enact significant rate reductions when the easing...

Continue Reading
Innovative Pet Bed Design Revolutionizes Pet Comfort and Play

Updated Category News Views 181

Revolutionizing Pet Comfort with Unique Bed Design In a world where our pets deserve the best, one inventor has taken the initiative to create a pet bed that stands out. The LAY AND PLAY offers a distinctive design tailored especially for cats, ensuring that their needs for play and comfort are met. The inventor explained, “I wanted to invent an alternative pet bed that...

Continue Reading
Lithium Argentina Reveals Q3 2025 Insights and Future Plans

Updated Category News Views 315

Lithium Argentina's Third Quarter Highlights Lithium Argentina AG, a prominent player in the lithium sector, has recently unveiled its third quarter results for 2025. The company, recognized under the ticker symbols TSX: LAR and NYSE: LAR, showcases its ongoing commitment to improving operational performance and efficiency. Webcast and Executive Insights Today's webcast,...

Continue Reading